Shots:
- Roche has received the CE Mark approval for its Elecsys Apolipoprotein E4 biomarker test, an in-vitro diagnostic immunoassay to identify the presence of the ApoE4 gene variant in the bloodstream
- The assay was evaluated in a study of 607 subjects with cognitive complaints or objective memory impairment of unknown aetiology, where Elecsys ApoE4 assay showed 100% concordance with Sanger bidirectional sequencing for APOE4 genotyping, correctly identifying all carriers & non-carriers
- Elecsys ApoE4 is a minimally invasive blood test that identifies ApoE4 variant carriers, allowing efficient filtering of non-carriers & reserving genetic testing for those who need it
Ref: PRnewswire | Image: Roche | Press Release
Related News: Roche and Zealand Pharma Report P-II (ZUPREME-1) Trial Data on Petrelintide in Obesity
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
